{
  "docId": "019de075-8a55-750a-8008-603750933d71",
  "docSlug": "da8608bdf4ad385699d1340db7dce185",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 56,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "Swimmer plot visualization of clinical trial data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/20",
  "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
  "deckJsonHref": "/decks/019de075-8a55-750a-8008-603750933d71.json",
  "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.48,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Swimmer plot of patient treatment duration",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f40e1b1b-e916-493b-83ef-ed9a605ed8ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.08,
        "y": 0.75
      },
      "kind": "list",
      "text": "9/24 patients remain on treatment as of data cutoff; 1 has delayed progression >6 months; 8 others have potential to continue >6 months.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ccdd3ad-f66f-47c6-8624-93b0cbba3768",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: annotated LXH254C12201 Ph 2 trial data from Lebbe et al, ESMO 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d377f9bb-f6c8-4a2a-b28a-159c4ed115d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.96,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Phase 2 in NRASm melanoma: Analysis of pts who remain on treatment show potential for naporafenib + trametinib to demonstrate PFS benefit",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b3af70a-1bd0-4ee6-b47a-d331688ce202",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.74,
        "x": 0.13,
        "y": 0.15
      },
      "kind": "title",
      "text": "Duration of Exposure (months) for naporafenib 200 mg BID + trametinib 1 mg QD",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9720d11-b184-419b-9fe1-f64e04b6e3fe",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 15,
      "beatId": "0ba8dc28-f394-4539-9ceb-99555f1271c2",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document highlights the unmet needs and limitations of current treatments for NRASm metastatic melanoma.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    },
    {
      "to": 20,
      "from": 13,
      "beatId": "f286216e-8f02-4c67-ba26-139ada264780",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document provides evidence and proof of Erasca's pipeline and its potential effectiveness.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1dd29138-5e83-440f-a4ea-0cd29a31a0c3",
      "evidence": "The document highlights the limitations of current treatments and the potential benefits of Erasca's pipeline.",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet needs in cancer treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}